Organoids for Preclinical Disease Modeling and Personalized Medicine

Lieferzeit: Lieferbar innerhalb 14 Tagen

213,99 

Stem Cell Biology and Regenerative Medicine 78

ISBN: 3032100232
ISBN 13: 9783032100238
Herausgeber: Ozge Sezin Somuncu
Verlag: Springer Verlag GmbH
Umfang: viii, 158 S., 1 s/w Illustr., 10 farbige Illustr., 158 p. 11 illus., 10 illus. in color.
Erscheinungsdatum: 03.01.2026
Auflage: 1/2026
Produktform: Gebunden/Hardback
Einband: Gebunden
Artikelnummer: 7700651 Kategorie:

Beschreibung

Organoid technologies are preclinical models in which drug responses or radiotherapies are determined very closely to patient response. While until the recent past there were no three-dimensional systems in which the entire cellular content of an organ could be reflected, we can now create the physiological and structural features of an organ in vitro and model a disease effectively. As these diseases may be developmental defects, chronic diseases can also be investigated in detail at the gene and protein level with these systems. In terms of developmental biology, thanks to the use of organoids, it is possible to learn the physiological internal dynamics of organs and to model diseases other than cancer. Chapters include introductions to their respective topics, recent advancements and how future applications can be implemented to organoid models. Organoids for Preclinical Disease Modeling and Personalized Medicine serves as an aid to researchers working in this vital area of research.

Autorenporträt

ÖzgeSezin Somuncu is the Organoid Center Director and Senior Scientist in the Department of Radiation Oncology at DanaFarber Cancer Institute. Her research focuses on cancer biology, with special expertise in patientderived organoids, DNA damage and repair mechanisms (notably replication stress, USP1 and PARG pathways), and precision oncology. She earned her PhD from Yeditepe University and has held academic positions including Assistant Professor at Bahçesehir University. Her recent work has concentrated on identifying functional biomarkers for drug sensitivity in ovarian cancer models. She has authored numerous peerreviewed publications, contributed to patent applications, and currently leads collaborative translational projects aimed at improving therapeutic strategies. She currently leads and supports organoid-based translational research, oversees collaborative studies between lab researchers and clinicians and helps integrate organoids into preclinical drug development pipelines. 

Herstellerkennzeichnung:


Springer Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

E-Mail: juergen.hartmann@springer.com

Das könnte Ihnen auch gefallen …